U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997198) titled 'Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities' on May 21.
Brief Summary: The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population. Compare movement disorder deutetrabenazine treatment response in persons with IDD to response seen in patients without IDD treated with deutetrabenazine in other treatment settings (per literature review). Compare global deutetrabenazine treatment response with validated instruments.
In addition, we plan to:
* Assess the safety of deutetrabenazine in the treatment of TD...